LeHavreV1, Ncbi, Merge, bibRecord, 000484

Haemodialysis of pyrazinamide in uraemic patients.

Identifieur interne : 000484 ( Ncbi/Merge ); précédent : 000483; suivant : 000485

Haemodialysis of pyrazinamide in uraemic patients.

Auteurs : C. Lacroix [France] ; A. Hermelin ; R. Guiberteau ; C. Guyonnaud ; J. Nouveau ; H. Duwoos ; O. Lafont

Source :

European journal of clinical pharmacology [ 0031-6970 ] ; 1989.

RBID : pubmed:2612545

English descriptors

KwdEn :
- Adult, Biotransformation, Chromatography, High Pressure Liquid, Female, Humans, Male, Pyrazinamide (blood), Pyrazinamide (metabolism), Pyrazinamide (pharmacokinetics), Renal Dialysis, Uremia (blood).
MESH :
- chemical , blood : Pyrazinamide.
- chemical , metabolism : Pyrazinamide.
- chemical , pharmacokinetics : Pyrazinamide.
- blood : Uremia.
- Adult, Biotransformation, Chromatography, High Pressure Liquid, Female, Humans, Male, Renal Dialysis.

Abstract

The pharmacokinetics of PZA during haemodialysis were determined in 6 patients with chronic renal impairment after a single oral dose of 25.7 (1.9) mg.kg-1. The dialysis clearance of PZA and of its metabolites were: pyrazinamide 132 ml.min-1; pyrazinoic acid 121 ml.min-1; 5-hydroxy-pyrazinamide 107 ml.min-1; 5-hydroxy-pyrazinoic acid 118 ml.min-1. The average amount extracted during a dialysis session of 4.1 h was 926 mg after an oral dose of 1700 mg. The high dialysability shows that PZA can properly be administered at the end of each dialysis session in the usual dose of 25 to 30 mg.kg-1.

PubMed: 2612545

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 000449
to stream PubMed, to step Curation: 000449
to stream PubMed, to step Checkpoint: 000449

Links to Exploration step

pubmed:2612545

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Haemodialysis of pyrazinamide in uraemic patients.</title>
<author><name sortKey="Lacroix, C" sort="Lacroix, C" uniqKey="Lacroix C" first="C" last="Lacroix">C. Lacroix</name>
<affiliation wicri:level="1"><nlm:affiliation>Unités de Pharmacocinétique, Centre Hospitalier Général, Le Havre, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Unités de Pharmacocinétique, Centre Hospitalier Général, Le Havre</wicri:regionArea>
<placeName><settlement type="city">Le Havre</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hermelin, A" sort="Hermelin, A" uniqKey="Hermelin A" first="A" last="Hermelin">A. Hermelin</name>
</author>
<author><name sortKey="Guiberteau, R" sort="Guiberteau, R" uniqKey="Guiberteau R" first="R" last="Guiberteau">R. Guiberteau</name>
</author>
<author><name sortKey="Guyonnaud, C" sort="Guyonnaud, C" uniqKey="Guyonnaud C" first="C" last="Guyonnaud">C. Guyonnaud</name>
</author>
<author><name sortKey="Nouveau, J" sort="Nouveau, J" uniqKey="Nouveau J" first="J" last="Nouveau">J. Nouveau</name>
</author>
<author><name sortKey="Duwoos, H" sort="Duwoos, H" uniqKey="Duwoos H" first="H" last="Duwoos">H. Duwoos</name>
</author>
<author><name sortKey="Lafont, O" sort="Lafont, O" uniqKey="Lafont O" first="O" last="Lafont">O. Lafont</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1989">1989</date>
<idno type="RBID">pubmed:2612545</idno>
<idno type="pmid">2612545</idno>
<idno type="wicri:Area/PubMed/Corpus">000449</idno>
<idno type="wicri:Area/PubMed/Curation">000449</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000449</idno>
<idno type="wicri:Area/Ncbi/Merge">000484</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Haemodialysis of pyrazinamide in uraemic patients.</title>
<author><name sortKey="Lacroix, C" sort="Lacroix, C" uniqKey="Lacroix C" first="C" last="Lacroix">C. Lacroix</name>
<affiliation wicri:level="1"><nlm:affiliation>Unités de Pharmacocinétique, Centre Hospitalier Général, Le Havre, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Unités de Pharmacocinétique, Centre Hospitalier Général, Le Havre</wicri:regionArea>
<placeName><settlement type="city">Le Havre</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hermelin, A" sort="Hermelin, A" uniqKey="Hermelin A" first="A" last="Hermelin">A. Hermelin</name>
</author>
<author><name sortKey="Guiberteau, R" sort="Guiberteau, R" uniqKey="Guiberteau R" first="R" last="Guiberteau">R. Guiberteau</name>
</author>
<author><name sortKey="Guyonnaud, C" sort="Guyonnaud, C" uniqKey="Guyonnaud C" first="C" last="Guyonnaud">C. Guyonnaud</name>
</author>
<author><name sortKey="Nouveau, J" sort="Nouveau, J" uniqKey="Nouveau J" first="J" last="Nouveau">J. Nouveau</name>
</author>
<author><name sortKey="Duwoos, H" sort="Duwoos, H" uniqKey="Duwoos H" first="H" last="Duwoos">H. Duwoos</name>
</author>
<author><name sortKey="Lafont, O" sort="Lafont, O" uniqKey="Lafont O" first="O" last="Lafont">O. Lafont</name>
</author>
</analytic>
<series><title level="j">European journal of clinical pharmacology</title>
<idno type="ISSN">0031-6970</idno>
<imprint><date when="1989" type="published">1989</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Biotransformation</term>
<term>Chromatography, High Pressure Liquid</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Pyrazinamide (blood)</term>
<term>Pyrazinamide (metabolism)</term>
<term>Pyrazinamide (pharmacokinetics)</term>
<term>Renal Dialysis</term>
<term>Uremia (blood)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Pyrazinamide</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Pyrazinamide</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Pyrazinamide</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Uremia</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Biotransformation</term>
<term>Chromatography, High Pressure Liquid</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Renal Dialysis</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The pharmacokinetics of PZA during haemodialysis were determined in 6 patients with chronic renal impairment after a single oral dose of 25.7 (1.9) mg.kg-1. The dialysis clearance of PZA and of its metabolites were: pyrazinamide 132 ml.min-1; pyrazinoic acid 121 ml.min-1; 5-hydroxy-pyrazinamide 107 ml.min-1; 5-hydroxy-pyrazinoic acid 118 ml.min-1. The average amount extracted during a dialysis session of 4.1 h was 926 mg after an oral dose of 1700 mg. The high dialysability shows that PZA can properly be administered at the end of each dialysis session in the usual dose of 25 to 30 mg.kg-1.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2612545</PMID>
<DateCreated><Year>1990</Year>
<Month>3</Month>
<Day>1</Day>
</DateCreated>
<DateCompleted><Year>1990</Year>
<Month>03</Month>
<Day>01</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0031-6970</ISSN>
<JournalIssue CitedMedium="Print"><Volume>37</Volume>
<Issue>3</Issue>
<PubDate><Year>1989</Year>
</PubDate>
</JournalIssue>
<Title>European journal of clinical pharmacology</Title>
<ISOAbbreviation>Eur. J. Clin. Pharmacol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Haemodialysis of pyrazinamide in uraemic patients.</ArticleTitle>
<Pagination><MedlinePgn>309-11</MedlinePgn>
</Pagination>
<Abstract><AbstractText>The pharmacokinetics of PZA during haemodialysis were determined in 6 patients with chronic renal impairment after a single oral dose of 25.7 (1.9) mg.kg-1. The dialysis clearance of PZA and of its metabolites were: pyrazinamide 132 ml.min-1; pyrazinoic acid 121 ml.min-1; 5-hydroxy-pyrazinamide 107 ml.min-1; 5-hydroxy-pyrazinoic acid 118 ml.min-1. The average amount extracted during a dialysis session of 4.1 h was 926 mg after an oral dose of 1700 mg. The high dialysability shows that PZA can properly be administered at the end of each dialysis session in the usual dose of 25 to 30 mg.kg-1.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lacroix</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Unités de Pharmacocinétique, Centre Hospitalier Général, Le Havre, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hermelin</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Guiberteau</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y"><LastName>Guyonnaud</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Nouveau</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Duwoos</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lafont</LastName>
<ForeName>O</ForeName>
<Initials>O</Initials>
</Author>
</AuthorList>
<Language>ENG</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Germany</Country>
<MedlineTA>Eur J Clin Pharmacol</MedlineTA>
<NlmUniqueID>1256165</NlmUniqueID>
<ISSNLinking>0031-6970</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>2KNI5N06TI</RegistryNumber>
<NameOfSubstance UI="D011718">Pyrazinamide</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001711" MajorTopicYN="N">Biotransformation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002851" MajorTopicYN="N">Chromatography, High Pressure Liquid</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011718" MajorTopicYN="N">Pyrazinamide</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006435" MajorTopicYN="Y">Renal Dialysis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014511" MajorTopicYN="N">Uremia</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year>
<Month>1</Month>
<Day>1</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>1989</Year>
<Month>1</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>1989</Year>
<Month>1</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">2612545</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>France</li>
</country>
<settlement><li>Le Havre</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Duwoos, H" sort="Duwoos, H" uniqKey="Duwoos H" first="H" last="Duwoos">H. Duwoos</name>
<name sortKey="Guiberteau, R" sort="Guiberteau, R" uniqKey="Guiberteau R" first="R" last="Guiberteau">R. Guiberteau</name>
<name sortKey="Guyonnaud, C" sort="Guyonnaud, C" uniqKey="Guyonnaud C" first="C" last="Guyonnaud">C. Guyonnaud</name>
<name sortKey="Hermelin, A" sort="Hermelin, A" uniqKey="Hermelin A" first="A" last="Hermelin">A. Hermelin</name>
<name sortKey="Lafont, O" sort="Lafont, O" uniqKey="Lafont O" first="O" last="Lafont">O. Lafont</name>
<name sortKey="Nouveau, J" sort="Nouveau, J" uniqKey="Nouveau J" first="J" last="Nouveau">J. Nouveau</name>
</noCountry>
<country name="France"><noRegion><name sortKey="Lacroix, C" sort="Lacroix, C" uniqKey="Lacroix C" first="C" last="Lacroix">C. Lacroix</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/France/explor/LeHavreV1/Data/Ncbi/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000484 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000484 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/France
   |area=    LeHavreV1
   |flux=    Ncbi
   |étape=   Merge
   |type=    RBID
   |clé=     pubmed:2612545
   |texte=   Haemodialysis of pyrazinamide in uraemic patients.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i   -Sk "pubmed:2612545" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a LeHavreV1

This area was generated with Dilib version V0.6.25.
Data generation: Sat Dec 3 14:37:02 2016. Site generation: Tue Mar 5 08:25:07 2024

	Serveur d'exploration sur la visibilité du Havre
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la visibilité du Havre

Haemodialysis of pyrazinamide in uraemic patients.

Haemodialysis of pyrazinamide in uraemic patients.

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki